(Z)-3-(6-bromo-2,2-dimethylchromen-8-yl)-3-phenylprop-2-en-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (Z)-3-(6-bromo-2,2-dimethylchromen-8-yl)-3-phenylprop-2-en-1-ol
• 化学式: C₂₀H₁₉BrO₂
• 分子量: 371.3
• InChiKey: QIVSDVDCLGYFPS-MFOYZWKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• PKC DELTA INHIBITORS FOR USE AS THERAPEUTICS
  申请人：Faller, Douglas V.

  公开号：EP2897610A2

  公开（公告）日：2015-07-29
• [EN] PKC DELTA INHIBITORS FOR USE AS THERAPEUTICS<br/>[FR] INHIBITEURS DE PKC DELTA DESTINÉS À ÊTRE UTILISÉS COMME SUBSTANCES THÉRAPEUTIQUES
  申请人：FALLER DOUGLAS V

  公开号：WO2014047328A2

  公开（公告）日：2014-03-27

  The invention directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevent of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (Ib), (IIa), (IIb), (IIIa), (IIIb), (IVa), (IVb), and (V) as disclosed and described in Figures 11 and 12.